0JYO Stock Overview
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
BB Biotech AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF40.35 |
| 52 Week High | CHF49.75 |
| 52 Week Low | CHF35.45 |
| Beta | 0.83 |
| 1 Month Change | -11.42% |
| 3 Month Change | -9.43% |
| 1 Year Change | -10.54% |
| 3 Year Change | -52.59% |
| 5 Year Change | -34.97% |
| Change since IPO | 320.39% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0JYO | GB Capital Markets | GB Market | |
|---|---|---|---|
| 7D | -1.9% | 0.4% | 1.4% |
| 1Y | -10.5% | 5.8% | 1.1% |
Return vs Industry: 0JYO underperformed the UK Capital Markets industry which returned 5.8% over the past year.
Return vs Market: 0JYO underperformed the UK Market which returned 1.1% over the past year.
Price Volatility
| 0JYO volatility | |
|---|---|
| 0JYO Average Weekly Movement | 3.6% |
| Capital Markets Industry Average Movement | 4.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0JYO has not had significant price volatility in the past 3 months.
Volatility Over Time: 0JYO's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 10 | n/a | www.bbbiotech.ch/en/bb-biotech/ |
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology.
BB Biotech AG Fundamentals Summary
| 0JYO fundamental statistics | |
|---|---|
| Market cap | CHF2.22b |
| Earnings (TTM) | CHF307.74m |
| Revenue (TTM) | CHF270.74m |
7.2x
P/E Ratio8.2x
P/S RatioIs 0JYO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0JYO income statement (TTM) | |
|---|---|
| Revenue | CHF270.74m |
| Cost of Revenue | CHF0 |
| Gross Profit | CHF270.74m |
| Other Expenses | -CHF37.00m |
| Earnings | CHF307.74m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 26, 2024
| Earnings per share (EPS) | 5.61 |
| Gross Margin | 100.00% |
| Net Profit Margin | 113.67% |
| Debt/Equity Ratio | 13.9% |
How did 0JYO perform over the long term?
See historical performance and comparison